In this issue:
- Gut microbial L-ornithine and ustekinumab
- Dual biologic or small molecule therapy in paediatric IBD
- Ustekinumab drug clearance association with disease control
- First-line anti-TNF agents, ustekinumab and vedolizumab in IBD
- Multivariate prediction of risk of 90-day rehospitalisation
- Serum leucine-rich alpha2 glycoprotein biomarker for CD activity
- Faecal calprotectin from ileostomy output in CD patients
- Endoscopic dysplasia detection technologies in IBD
- Dose escalation of ustekinumab in IBD
- Science Blog: Miniproteins in IBD therapeutics
Please login below to download this issue (PDF)